Repligen Corporation to Present at Upcoming Investor Conferences
May 31, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
May 02, 2023 07:30 ET
|
Repligen Corporation
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP)...
Repligen to Report First Quarter 2023 Financial Results
April 18, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023....
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
March 14, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023 07:30 ET
|
Repligen Corporation
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currencyFull year revenue of $801.5 million represents year-over-year organic growth...
Repligen Appoints Martin D. Madaus to Board of Directors
February 09, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D....
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
February 08, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on...
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Corporation to Present at Upcoming Investor Conferences
November 08, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
November 01, 2022 07:30 ET
|
Repligen Corporation
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers base business growth of 29% for the...